Taspoglutide is a synthetic peptide that belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which are primarily used in the management of type 2 diabetes. It is designed to enhance insulin secretion in response to elevated blood glucose levels, thereby aiding in glycemic control. Taspoglutide exhibits a prolonged half-life compared to endogenous GLP-1, allowing for less frequent dosing. Its mechanism of action involves stimulating insulin release from pancreatic beta cells, inhibiting glucagon secretion, and promoting satiety, which can contribute to weight loss. The substance is characterized by its peptide structure, which includes specific amino acid sequences that confer its biological activity. Additionally, Taspoglutide has been studied for its potential cardiovascular benefits and effects on weight management. However, like other GLP-1 receptor agonists, it may have side effects, including gastrointestinal issues and potential risks of pancreatitis. Overall, Taspoglutide represents a promising therapeutic option in diabetes care, reflecting ongoing advancements in peptide-based medications.

Taspoglutide

275371-94-3: Taspoglutide is a synthetic peptide that belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which are primarily used in the management of type 2 diabetes. It is designed to enhance insulin secretion in response to elevated blood glucose levels, thereby aiding in glycemic control. Taspoglutide exhibits a prolonged half-life compared to endogenous GLP-1, allowing for less frequent dosing. Its mechanism of action involves stimulating insulin release from pancreatic beta cells, inhibiting glucagon secretion, and promoting satiety, which can contribute to weight loss. The substance is characterized by its peptide structure, which includes specific amino acid sequences that confer its biological activity. Additionally, Taspoglutide has been studied for its potential cardiovascular benefits and effects on weight management. However, like other GLP-1 receptor agonists, it may have side effects, including gastrointestinal issues and potential risks of pancreatitis. Overall, Taspoglutide represents a promising therapeutic option in diabetes care, reflecting ongoing advancements in peptide-based medications.

Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist(EC50 value of 0.06 nM),and for treatment of type 2 diabetes

CAS 275371-94-3

Taspoglutide

Taspoglutide

Ref: TM-T13091

Taspoglutide

Ref: BP-BPPG061